|
Market Closed -
NYSE
05:00:00 17/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 3.030 USD | -0.66% |
|
+17.90% | +68.33% |
| 11-11 | Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2026 | CI |
| 11-10 | Protalix BioTherapeutics, Inc., Q3 2026 Earnings Call, Nov 10, 2026 |
Evolution of the Average Target: Protalix BioTherapeutics, Inc.
Evolution of the Target Price: Protalix BioTherapeutics, Inc.
Changes in Analyst Recommendations: Protalix BioTherapeutics, Inc.
e33da0a69fba131e.L2eaxUXnqt8wjIAmXgp0kKp76ERQ2Md1Q30ogg4wWLU.fR3jgzyiwJ57v8tqbUQZ95s3mDA5l68GF09-6HtlKOp7E_P8K6PGhkn99w~d85675e25f09936fd43e9cc1b60c6e94
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
| - | - | +293.44% | ||||
| +1.38% | ||||||
| -2.22% | ||||||
| +5.69% | ||||||
| -2.05% | ||||||
| +9.32% | ||||||
| -3.71% | ||||||
| +16.57% | ||||||
| -7.27% | ||||||
| +3.98% | ||||||
| Average | +31.51% | |||||
| Weighted average by Cap. | +1.98% |


Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.050USD
Average target price
12.00USD
Spread / Average Target
+293.44%
High Price Target
12.00USD
Spread / Highest target
+293.44%
Low Price Target
12.00USD
Spread / Lowest Target
+293.44%
Analyst Consensus Detail
Consensus revision (last 18 months)
- Stock Market
- Stocks
- PLX Stock
- Consensus Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















